Brazil Warns EU of Retaliation Over Animal Products Ban 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Trump’s Arlington Arch Project Faces New Court Restrictions 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Milei Threatens Falkland Oil Firms With Sanctions 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Anthropic IPO Marketing Expected to Start in Mid-October 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
AfD Eyes Historic Win in Saxony-Anhalt Election 
Israeli Strikes Kill Four in Gaza, Including Two Children 
Trump Seeks Europe Repayment for U.S. Ukraine Military Aid 
Lavrov Accuses Germany of ‘Declaring War’ on Russia 
Add as a preferred source on Google
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over drug pricing. Miley, formerly Senior Vice President of Government Affairs at AbbVie, announced his appointment on LinkedIn, with Novo Nordisk confirming the news to Reuters.
The company stated that Miley will officially join in early November, overseeing global communications and public affairs. His extensive experience in the U.S. pharmaceutical sector is expected to help Novo strengthen its political and regulatory strategies in its largest market—the United States. A company source noted that Miley’s top priority will be managing relations with the Trump administration, which has recently intensified pressure on pharmaceutical firms to reduce prices.
Miley’s appointment aligns with new CEO Mike Doustdar’s efforts to regain investor confidence through a broad restructuring initiative aimed at improving competitiveness in the growing obesity drug market, particularly against Eli Lilly. The overhaul involves cutting about 9,000 jobs worldwide, including 5,000 in Denmark and several in the U.S.
In his LinkedIn post, Miley expressed optimism about enhancing Novo’s global communication and public affairs, noting his upcoming relocation to Denmark. Industry insiders say other major pharma companies have also been recruiting public affairs experts with strong Republican ties to navigate Washington’s policy landscape.
Shares of Novo Nordisk and Eli Lilly dropped on Friday following Trump’s statement that the price of Ozempic—Novo’s diabetes drug containing the same ingredient as its popular weight-loss drug Wegovy—would be lowered.
Miley brings nearly two decades of experience in pharmaceutical government relations, with past roles at Abbott and Pfizer, making him a pivotal figure in Novo’s next phase of global engagement.
